The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced pancreatic cancer: a single-arm, phase II study - PubMed
3 hours ago
- #immunotherapy
- #pancreatic cancer
- #clinical trial
- Phase II study (NCT02648282) evaluated a combination of GM-CSF-secreting pancreatic cancer vaccine (GVAX), pembrolizumab, and stereotactic body radiation therapy (SBRT) in 58 patients with locally advanced pancreatic cancer (LAPC).
- 54 evaluable patients received two cycles of immunotherapy and SBRT, with 64.8% deemed potentially resectable; 24 underwent R0/R1 resections (91.7% R0).
- Median distant metastasis-free survival (DMFS) was 9.8 months for all patients, but resected patients achieved 20.3 months.
- Median overall survival (OS) from immunotherapy start was 21.8 months (29.7 months for resected vs. 12.1 months for unresected). From diagnosis, median OS was 28.2 months (36.7 months resected vs. 19.7 months unresected).
- The regimen showed promising efficacy, especially for resected patients, with a manageable safety profile.
- Authors disclosed conflicts of interest, including grant support and consultancy roles with pharmaceutical companies.